XII Medical is a technology company.
XII Medical has raised $75.0M across 2 funding rounds.
XII Medical has raised $75.0M in total across 2 funding rounds.
XII Medical has raised $75.0M in total across 2 funding rounds.
XII Medical's investors include Aperture Venture Partners.
XII Medical is a clinical-stage medical technology company developing minimally invasive neuromodulation therapies for obstructive sleep apnea (OSA), a common sleep disorder affecting millions worldwide.[1][3][4][6] The company builds an innovative outpatient device platform that simplifies implantation, enhances patient compliance, and improves outcomes compared to existing treatments like CPAP machines or bulkier implants, primarily serving patients with moderate to severe OSA in the healthcare sector.[1][2][3][4] Founded in 2017 and headquartered in Union City, California, XII Medical has raised approximately $75M total, including a $30M Series A in 2022 and a $45M Series B in August 2024 led by Omega Funds and Intuitive Ventures, signaling strong growth momentum backed by investors like Ajax Health, Cleveland Clinic, and Aperture Venture Partners.[1][4][5]
XII Medical was founded in 2017 in Union City, California, originally as EnHale Medical, Inc., before rebranding to focus on its core mission.[1] Key leadership includes Garrett Schwab as President and CEO, who oversees operations and clinical advancement, and Anthony Natale, M.D., as Executive Chairman, a physician-entrepreneur with decades of experience in airway disorders.[1][4] The idea emerged from addressing gaps in OSA treatments—such as poor compliance with CPAP and limitations of prior implants—leading to a platform emphasizing minimally invasive neuromodulation.[3][4][6] Early traction came via Cleveland Clinic as a founding investor, followed by a $30M Series A in 2022 led by Ajax Health, with pivotal endorsements from experts like Duke Rohlen of Ajax Health highlighting the team's unified focus on value creation.[1][5]
XII Medical rides the surging demand for OSA solutions amid rising awareness of sleep health's impact on cardiovascular disease, productivity, and quality of life, with hundreds of millions affected globally.[4] Timing aligns with advances in neuromodulation and minimally invasive devices, fueled by market forces like aging populations, post-pandemic sleep disorder spikes, and investor interest in medtech (evidenced by its $45M Series B in 2024).[1][4][5] It influences the ecosystem by challenging incumbents like Inspire Medical, expanding access through simpler tech, and fostering collaborations with clinics and VCs, potentially accelerating adoption of neuromodulation beyond OSA.[1][3][4]
XII Medical is poised to advance its investigational platform toward commercialization, leveraging Series B funds for clinical trials, team expansion, and partnerships to achieve FDA approval and market entry.[4] Trends like AI-enhanced diagnostics, personalized medtech, and value-based healthcare will shape its path, amplifying its edge in patient-centric OSA therapies.[6] Its influence may evolve by setting new standards for neuromodulation accessibility, drawing more strategic investments, and impacting the $10B+ sleep apnea market—transforming a once-overlooked disorder into a medtech success story.[1][4]
XII Medical has raised $75.0M across 2 funding rounds. Most recently, it raised $45.0M Series B in August 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2024 | $45.0M Series B | Aperture Venture Partners | |
| May 1, 2022 | $30.0M Series A | Aperture Venture Partners |